Durvalumab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

In a Phase III, double-blind, randomized, placebo-controlled trial, researchers assigned patients to receive durvalumab at a dose of 1500 mg, durvalumab plus tremelimumab at a dose of 75 mg, or placebo every four weeks for up to 24 months.